Skip to main content
. Author manuscript; available in PMC: 2021 Mar 17.
Published in final edited form as: Adv Funct Mater. 2020 Feb 3;30(12):1908961. doi: 10.1002/adfm.201908961

Figure 3. KT-1 improves in vivo outcomes in a CD8+ T cell-dependent manner and leads to adaptive enrichment of tumor PD-L1 expression.

Figure 3.

(A) Individual tumor growth curves and (B) animal survival rate over time after treatments with saline, EPI and KT-1. The arrows indicate the treatment regimens. (C) Individual tumor growth curves and (D) animal survival rate over time after co-treatment with CD8-depleting antibodies and KT-1. The arrows indicate the treatment regimens. (E) Flow cytometry scatter plot representation of CD8+ T cells and CD4+Foxp3+ Tregs, and statistics of (F) tumor recruitment of CD8+ T cells, (G) Tregs, (H) CD8+ T cells to Treg ratio, and (I) PD-L1 expressions within tumor cells after chemotherapy with EPI and KT-1 indicated in (A). (J) Individual tumor growth curves and (K) animal survival rate over time after saline, EPI, and KT-1 treatments in combination with α-PD-L1. The arrows indicate the treatment regimens. CR, complete tumor regression. n=5–10, *P< 0.05, n.s., not significant, one-way ANOVA with Tukey’s multiple comparison test, box plots represent whiskers, 5th to 95th percentile.